The Relationship between Diabetes Mellitus and Hypertension with Pemphigus Vulgaris in Pemphigus Vulgaris Patients
Abstract
Pemphigus vulgaris (PV) is a chronic autoimmune skin disease that manifests as loose vesicles and bullae that affect the mucosa and skin. The first-line therapy for PV is systemic corticosteroids. Although corticosteroid therapy is effective as treatment for pemphigus vulgaris, long-term use of corticosteroids causes various complications such as diabetes mellitus and hypertension. Objectives to examine the relationship of pemphigus vulgaris with diabetes mellitus and hypertension. This study is a retrospective analytic study with a cross sectional approach with a sample size of sixteen people with pemphigus vulgaris. This research was conducted in March – August 2022 at Dr. M. Djamil Hospital in Padang. Relationship analysis is performed using Fisher's exact test by comparing the incidence of diabetes mellitus and hypertension in patients with pemphigus vulgaris with patients with other autoimmune bullous diseases. There is no significant relationship between pemphigus vulgaris and diabetes mellitus (p = 0.133) and hypertension (p = 0.253). The profile of patients with pemphigus vulgaris is also obtained: the annual incidence of PV is 3.2 cases/year; the majority of PV patients are women, with a female to male ratio of 1:0,78; the majority of PV patients are in the 40-60 year age group; the occupation of the most PV patients is housewives; and the majority of clinical manifestations of patients with PV are found on the skin and mucous membranes. There is no significant relationship between pemphigus vulgaris with diabetes mellitus and hypertension.
References
Tamgadge S, Bhatt D, Pereira T, Tamgadge A, Bhalerao S. Pemphigus vulgaris. Contemp Clin Dent. 2011 [cited 2021 Jun 28];2(2):134. Available from: http://www.contempclindent.org/text.asp?2011/2/2/134/83074
Benny E. Wiryadi. Dermatosis vesikobulosa kronik. In: Menaldi SL, Bramono K, Indriatmi W, editors. Ilmu Penyakit Kulit dan Kelamin. 7th ed. Jakarta: Badan Penerbitan FKUI; 2016. p. 234–8. Available from: http://www.bpfkui.com/
Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med. 2007 May [cited 2021 Nov 5];11(3):462. Available from: /pmc/articles/PMC3922353/
Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006 May 1 [cited 2021 Nov 5];116(5):1159. Available from: /pmc/articles/PMC1451217/
Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, et al. Pemphigus. Nat Rev Dis Prim. 2017 May 11 [cited 2021 Nov 20];3:17026. Available from: /pmc/articles/PMC5901732/
Kridin K, Zelber-Sagi S, Khamaisi M, Cohen AD, Bergman R. Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region. J Am Acad Dermatol. 2016 Nov 1 [cited 2021 Jun 30];75(5):925–30. Available from: https://pubmed.ncbi.nlm.nih.gov/27614531/
Meyer N, Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev. 2010;9(5):A379–82. Available from: http://dx.doi.org/10.1016/j.autrev.2009.10.009
Porro AM, Seque CA, Ferreira MCC, E Silva Enokihara MMS. Pemphigus vulgaris. An Bras Dermatol. 2019 May 1 [cited 2021 Jul 1];94(3):264–78. Available from: /pmc/articles/PMC6668932/
Asilian A, Yoosefi A, Faghini G. Pemphigus vulgaris in Iran: epidemiology and clinical profile. Skinmed. 2006 [cited 2021 Dec 1];5(2):69–71. Available from: https://pubmed.ncbi.nlm.nih.gov/16603836/
Wardhana M, Rusyati LM. Prevalence And Quality Of Life Of Pemphigus Patients At Sanglah General Hospital Bali-Indonesia. Bali Med J. 2013;2(1):42–5.
Joly P, Horvath B, Patsatsi, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatology Venereol. 2020 Sep 1 [cited 2021 Nov 7];34(9):1900–13. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16752
Darjani A, Nickhah N, Emami MHH, Alizadeh N, Rafiei R, Eftekhari H, et al. Assessment of the Prevalence and Risk Factors Associated With Glucocorticoid-Induced Diabetes Mellitus in Pemphigus Vulgaris Patients. Acta Med Iran. 2017 Aug 19 [cited 2022 Jan 13];78(11):375–80. Available from: https://acta.tums.ac.ir/index.php/acta/article/view/5561
Hsu DY, Brieva J, Nardone B, West D, Silverberg JI. Association of pemphigus and systemic corticosteroid use with comorbid health disorders: A case-control study. Dermatol Online J. 2017 [cited 2022 Jan 12];23(12):1–1. Available from: https://escholarship.org/uc/item/1vk2m30m
Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: A population-based cohort study. CMAJ. 2020 Mar 23 [cited 2022 Jan 17];192(12):E295–301. Available from: https://www.cmaj.ca/content/192/12/E295
Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clin Ther. 2017 Nov 1 [cited 2022 Jan 17];39(11):2216–29. Available from: https://pubmed.ncbi.nlm.nih.gov/29055500/
Diana EDN, Nugraha W, Rahma A, Oktafiani FA, Widyaswari R, Irawanto ME. Profil Pemphigus Vulgaris Di Instalasi Rawat Inap RSUD Dr . Moewardi Surakarta Periode Januari 2014-Desember 2019. Medicinus. 2021;34(3):27–34.
Surya N. Karakteristik Pasien Pemfigus Vulgaris Di Rsup H. Adam Malik Medan Periode Tahun 2009-2013. 2014;
Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus. 2020 May 13 [cited 2022 Aug 13];12(5). Available from: /pmc/articles/PMC7292717/
Stanley JR. Pemphigus. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, editors. Fitzpatrick’s Dermatology in General Medicine. Seventh. New York: Mc Graw Hill; 2008. p. 459–68.
Ingold CJ, Khan MA. Pemphigus Vulgaris. 2021 May 1 [cited 2021 Jul 1]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK560860/
Goronzy JJ, Weyand CM. Immune aging and autoimmunity. Cell Mol Life Sci. 2012 May [cited 2022 Aug 14];69(10):1615. Available from: /pmc/articles/PMC4277694/
Vadasz Z, Haj T, Kessel A, Toubi E. Age-related autoimmunity. BMC Med. 2013 Apr 4 [cited 2022 Aug 14];11(1):94. Available from: /pmc/articles/PMC3616810/
Patel F, Wilken R, Patel FB, Sultani H, Bustos I, Duong C, et al. Pathophysiology of Autoimmune Bullous Diseases: Nature Versus Nurture. Indian J Dermatol. 2017 May 1 [cited 2021 Oct 22];62(3):262. Available from: /pmc/articles/PMC5448260/
Wohl Y, Brenner S. Pemphigus in Israel - An epidemiologic analysis of cases in search of risk factors. Isr Med Assoc J. 2003;5(6):410–2.
Fisher KR, Higginbotham R, Frey J, Granese J, Pillow J, Skinner RB. Pesticide-associated pemphigus vulgaris. Cutis. 2008;82(1):51–4.
Heelan K, Mahar AL, Walsh S, Shear NH. Pemphigus and associated comorbidities: a cross-sectional study. Clin Exp Dermatol. 2015 Aug 1 [cited 2022 Jan 15];40(6):593–9. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/ced.12634
Phan K, Mangkorntongsakul V, Ramachandran V, Loya A, Smith SD. Pemphigus and diabetes mellitus: a systematic review and meta-analysis. Int J Dermatol. 2021 Jan 1 [cited 2022 Jan 13];60(1):e1–3. Available from: https://pubmed.ncbi.nlm.nih.gov/33070309/
Cho N, Kirigia J, Ogurstova K, Reja A. IDF Diabetes Atlas 10th Edition [Internet]. 10th Edtio. Boyko JE, Magliano JD, Karuranga S, Piemonte L, Riley P, Saeedi P, et al., editors. International Diabetes Federation; 2021. 1–150 p. Available from: www.diabetesatlas.org
Askin O. A Retrospective Analysis of Pemphigus Vulgaris Patients: Demographics, Diagnosis, Co-morbid Diseases and Treatment Modalities Used. North Clin Istanbul. 2020;
Copyright (c) 2025 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
